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Abstract
Background: HIV-1 genotypic susceptibility scores (GSSs) were proven to be significant prognostic factors of fixed
time-point virologic outcomes after combination antiretroviral therapy (cART) switch/initiation. However, their
relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is
able to predict how long a new cART regimen will remain effective has never been designed.
Methods: We analyzed patients of the Italian ARCA cohort starting a new cART from 1999 onwards either after
virologic failure or as treatment-naïve. The time to virologic failure was the endpoint, from the 90
th day after
treatment start, defined as the first HIV-1 RNA > 400 copies/ml, censoring at last available HIV-1 RNA before
treatment discontinuation. We assessed the relative hazard/importance of GSSs according to distinct interpretation
systems (Rega, ANRS and HIVdb) and other covariates by means of Cox regression and random survival forests
(RSF). Prediction models were validated via the bootstrap and c-index measure.
Results: The dataset included 2337 regimens from 2182 patients, of which 733 were previously treatment-naïve.
We observed 1067 virologic failures over 2820 persons-years. Multivariable analysis revealed that low GSSs of cART
were independently associated with the hazard of a virologic failure, along with several other covariates. Evaluation
of predictive performance yielded a modest ability of the Cox regression to predict the virologic endpoint
(c-index≈0.70), while RSF showed a better performance (c-index≈0.73, p < 0.0001 vs. Cox regression). Variable
importance according to RSF was concordant with the Cox hazards.
Conclusions: GSSs of cART and several other covariates were investigated using linear and non-linear survival
analysis. RSF models are a promising approach for the development of a reliable system that predicts time to
virologic failure better than Cox regression. Such models might represent a significant improvement over the
current methods for monitoring and optimization of cART.
Background
Modern combination antiretroviral therapy (cART) can
suppress plasma viral load to undetectable levels in a
large proportion of HIV-1 infected patients. The risk for
a patient to experience virologic failure has been
decreasing consistently during the last decade in high-
income countries [1-5].
Part of this high rate of virologic success may be due to
the increasing ability of more potent and tolerable antire-
troviral drugs targeting a wider range of molecular tar-
gets, providing physicians the opportunity to tailor cART
r e g i m e n sa c c o r d i n gt op a t i e n t s ’ background and to man-
age treatment failure promptly. Additionally, better
understanding of the mechanisms of drug resistance
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individual’s virus genotype. Although the prevalence of
drug resistance seems to be decreasing in recent years
[6], despite modern cART options [7], drug resistance
remains a concern in chronically infected patients with a
long treatment history and in treatment-naïve patients
who have been infected with drug resistant isolates [8].
Overall, patients remain at risk of developing drug
resistance.
Genotypic susceptibility scores (GSSs) have been devel-
oped for interpreting HIV-1 drug susceptibility based on
the sequence of the virus genome coding for drug targets.
GSSs usually consist of a set of general rules for scoring
susceptibility to individual drugs. These systems are
curated and updated by panels of experts and made freely
available via the internet, and in some cases, as web-
services. The most popular systems include the Stanford
HIVdb [9], Agence Nationale de Recherche sur le Sida
(ANRS) [10], and Rega [11] algorithms. Recently,
machine learning methods have been also introduced to
model HIV-1 drug resistance and to optimize cART
design. These machine learning methods explore a larger
set of variables besides the viral genotype (such as viral
load, CD4+ T cell counts, demographic information,
treatment history), and include techniques such as artifi-
cial neural networks [12], mutagenetic trees [13], Baye-
sian networks [14], and random forests [15]. Both GSSs
and machine learning approaches have been proven to
usefully predict virologic outcome at fixed time points
(e.g. n-weeks) after cART initiation or switch [14-18].
T h es t a t e - o f - t h ea r ts y s t e m s ,a v a i l a b l ea sf r e ew e b -
services, are able to select a set of suitable cARTs for a
patient, given the patient’s viral genotype and other back-
ground information, ensuring the maximal probability
of viral load reduction after n-weeks of uninterrupted
treatment [19,20].
Systems that predict the actual time to virologic failure,
indicated by a viral load rebound following a cART-
induced viral load reduction, or no viral load reduction
after a few months of uninterrupted therapy, have not
been developed yet. However, GSSs have been already
associated with the time for achieving an undetectable
viral load [18]. In this work we explore the predictive
ability of linear and non-linear survival models with
respect to the time to virologic failure endpoint, along
with its prognostic factors. A model that could predict an
individual’s duration of virologic success with a cART
regimen would provide valuable information in tailoring
cART choice.
Methods
Study design
We considered patients enrolled in the Antiretroviral Resis-
tance Cohort Analysis (ARCA), a national observational
cohort [21] of HIV-1-infected patients followed up at > 100
clinical and laboratory units in Italy. At the time of this
study, data from > 20,000 patients and > 23,000 HIV-1 pol
gene sequences were available. Patients are anonymized
and included in the ARCA database after signature of an
informed consent to provide their data for academic not-
for-profit studies. The ARCA initiative is compliant with
the Declaration of Helsinki, and each participating centre is
subject to a local ethics committee that follows national
(and European where applicable) regulations.
Eligible patients were those starting a new cART from
January 1999 onwards, comprising 2 nucleotide or nucleo-
side reverse transcriptase inhibitors (NRTI) plus either
another NRTI or a non-nucleoside reverse transcriptase
inhibitor (NNRTI), or a protease inhibitor (PI), or a ritona-
vir-boosted protease inhibitor (PI/r). Treatments included
both a new therapy after virologic failure (defined as an
HIV-1 RNA > 400 copies/ml while on therapy) and a first-
line therapy in drug-naïve patients. Further selection cri-
teria were a cART duration of more than 90 days, and the
availability of at least one subsequent HIV-1 RNA deter-
mination after 90 days, using ultra-sensitive assays.
Patients were excluded that had cART switches due to
treatment simplification or early (e.g. < 90 days) changes
of one or more drugs associated with tolerability/adher-
ence issues.
The study endpoint was the time to virologic failure,
quantified as the first HIV-1 RNA > 400 copies/ml begin-
ning from the 90
th day after the cART start date and
before the treatment discontinuation date. If the cART
had not been discontinued yet, any HIV-1 RNA determi-
nation after the 90
th day of therapy was to be considered.
Data were censored at the last available HIV-1 RNA
determination < = 400 copies/ml available before the
treatment stop date, ignoring HIV-1 RNA determinations
after the cART discontinuation.
The following variables were coupled with each
patient’s record of cART switch/initiation and subse-
quent HIV-1 RNA determinations: calendar year; base-
line HIV-1 RNA, obtained within [-90, 0] days from the
cART start date, without other treatment changes during
that time interval; baseline CD4+ T cell count, [-90, +30]
days from the cART start date; age; gender; mode of
HIV-1 transmission; nationality; previous AIDS-defining
events, hepatitis B/C virus co-infection (either HBsAg or
HCV antibody positive serostatus); time passed from the
first HIV-1 positive antibody test to the first cART initia-
tion; duration of prior antiretroviral exposure; number of
previous antiretroviral therapy switches (any drug change
for any reason); previous drug class exposures (combina-
tions of NRTI/NNRTI/PI/other classes); previous subop-
timal treatment (less than three drugs in a regimen);
achievement of an HIV-1 RNA < = 50 copies/ml at any
time point during the cART follow up; a baseline HIV-1
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protease and positions 1-250 in the reverse transcriptase),
obtained within [-90, +15] days from the cART start date,
without other therapies used during that time interval
except the failing regimen, when applicable.
T h eb a s e l i n eH I V - 1g e n o t y p ew a ss u c c e s s i v e l yp r o -
cessed by calculating the GSS using the latest available
version from 3 interpretation systems (Rega 8.0.2, ANRS
2009.07, and HIVdb 6.0.9) with respect to the associated
cART. We used the standard susceptible/intermediate/
resistant categorization for all GSS, as by the output by
the HIVdb web-service [9], which were assigned the
numerical values of 1.0/0.5/0.0, respectively. The alge-
braic sum of GSS, calculated for drugs included in the
cART coupled to each genotype, was regarded as the
overall GSS of that cART regimen. Viral subtype was
determined with the Rega subtyping tool [22]. Unas-
signed subtypes were defined as undetermined.
Statistical analysis
Cox multivariable proportional hazard regression (with
robust variance estimation via a grouped jackknife) [23]
and random survival forests (RSF) [24] were considered
(with 30 to 100 single trees to be grown).
The Cox proportional hazard model is a general non-
parametric regression technique which is not based on
any assumptions concerning the underlying survival dis-
tribution. The model assumes that the underlying
hazard rate (rather than survival time) is a function of
the independent covariates. Let Yi denote the observed
time (either censoring time or event time) for subject i,
and let Ci be the indicator that the time corresponds to
an event (i.e. if Ci = 1 the event occurred and if Ci =0
the time is a censoring time). The hazard function Λ(t|
X) for the Cox proportional hazard model has the form
 (t|X)= 0(t)e(β1x1+...+βpxp)
This expression gives the hazard at time t for an indi-
vidual with covariate vector (explanatory variables) X.
The term Λ0(t) is called the baseline hazard, and it is
the hazard for the respective individual when all inde-
pendent variable values are equal to zero. The model is
called proportional hazard because, while no assump-
tions are made about the shape of the underlying hazard
function, the model equations specify a multiplicative
relationship between the underlying hazard function and
the log-linear function of the covariates. There is a log-
linear relationship between the independent variables
and the underlying hazard function. In addition, given
two observations with different values for the indepen-
dent variables, the ratio of the hazard functions for
those two observations does not depend on time.
RSF are an extension used to analyze censored data of
the random forests machine-learning method, an
ensemble of several decision trees for classification and
regression. A random survival tree is a special form of
decision tree for survival analysis. The tree is con-
structed using a training data set made of observation
data points of time, status/event, and associated predic-
tor covariates. A binary tree is grown by inferring node
splits upon the set of covariates as follows. The space of
observations is recursively divided into two disjoint sub-
spaces, thus inferring a node split, based on an optimal
cut-off value of a predictor. The log-rank statistic is
used usually as a criterion for node splitting in survival
trees. In detail, a proposed split at node h on a given
predictor x t a k e sa l w a y st h ef o r mx ≤ c and x >c.T h i s
split induces two children nodes and two sub-sets of
survival data. A good split should maximize survival dif-
ferences across the two sets of data. Let t1 <t2 < ... <tn
be the distinct death times in the parent node h,a n dl e t
di,j and Yi,j equal the number of deaths and individuals
at risk at time ti in the children nodes j =1 ,2 .N o t e
that Yi,j is the number of individuals in the child node j
who are alive at time ti, or who have an event (death) at
time ti. The log-rank statistics for a node split at value c
for a variable x is
L(x,c)=
n 
i=1

di,1 − Yi,1
di,1
Yi


n 
i=1
Yi,1
Yi

1 −
Yi,1
Yi

Yi − di
Yi − 1

di
T h el a r g e rt h ea b s o l u t ev a l u ef o rL( x , c )is, the better
the split is. Each tree node contains the number of total
and censored observations falling into the current cate-
gory, as well as a Kaplan-Maier estimation of the cumu-
lative survival for the group is calculated at the end
nodes. Since the predictive performance of one survival/
decision tree can be poor, different trees can be com-
bined together to obtain improved performance. RSF are
an ensemble average of different survival trees. Each tree
i sg r o w no nd i f f e r e n tb o o t s t r a ps a m p l e so ft h eo r i g i n a l
data set, and a randomization is introduced in the recur-
sive node splitting phase by considering a random sub-
set of predictors at each step. These characteristics
enable to approximate complex functions with a gener-
ally low generalization error. One theoretical advantage
of RSF over the Cox regression is that the latter relies
on the restrictive assumption of the proportional
hazards. In addition, RSF manage automatically the
non-linear interactions among variables, whilst in Cox
regression non-linear and higher-order interactions need
to be explored explicitly.
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whole study population and on the subset of therapy-
naïve patients. An additional sensitivity analysis was car-
ried out by considering only those patients with at least
two follow-up HIV-1 RNA determinations, where a
HIV-1 RNA viral load < = 50 copies/ml occurred at any
time point during the cART follow up.
The predictive ability of the RSF and Cox regression
was evaluated by means of the Harrell’s c-index measure
[25], comparing either linear predictions of Cox regres-
sion or mortality rates of RSF against observed time/
event pairs, using the bootstrap .632 method (100 runs)
for assessing the generalization error on unseen data
[26]. The c-index is defined as the probability of agree-
ment for any two randomly chosen observations, where
agreement means that the observation with the shorter
survival time of the two also has the larger risk score. A
previous study in the different context of breast cancer
research successfully used the c-index to compare RFS
and Cox regression [27].
The free software environment for statistical comput-
ing and graphics “R” was employed for all statistical ana-
lyses and graph generations [28]. Besides the “base”
package, the “survival”, “randomSurvivalForest”,a n d
“Hmisc” libraries were used to fit Cox regression mod-
els, RSF and to calculate c-index statistics, respectively.
Results
A total of 2,337 cART regimens from 2,158 patients
were considered. The proportion of patients who were
previously therapy-naïve was 34% (n = 733). Table 1
summarizes patients’ characteristics.
We observed 1,067 virologic failures over 2,820 person
years of follow-up (rate = 37.8 per 100 person years). By
Kaplan-Meier estimation, median (95% CI) time to viro-
logic failure was 659 (533-784) days for all patients, and
2,510 (1,715-N/A) days for those previously therapy-
naïve. By two years, the estimated proportion of patients
not experiencing virologic failure was 0.48 (0.46-0.51)
when considering the whole set of patients, and 0.71
(0.67-0.75) for those previously therapy-naïve.
Multivariable Cox analysis revealed that higher GSSs
(each fitted in separate models including the other cov-
ariates), a more recent calendar year, patients adminis-
tered 2NRTI+1PI/r, as compared to those undertaking
2NRTI+1NNRTI, and younger age were independently
associated with a decreased hazard of virologic failure.
Conversely, a higher HIV-1 RNA, a lower CD4+ count,
and previous drug class exposure were associated with
an increased hazard. Table 2 summarizes the results.
Variable importance and partial standardized mortality
plots of RSF (fitted using 100 trees) in general con-
firmed the Cox hazards (see Additional file 1, supple-
mentary figures S1 and S2).
The evaluation of extra-sample predictive performance
(via the bootstrap .632 method, on 100 runs) is shown in
Figure 1. In detail, the multivariable Cox models fitted
with different GSSs yielded an average (st.dev) c-index of
0.7060 (0.007) for Rega, 0.7048 (0.007) for ANRS, and
0.7068 (0.007) for HIVdb. As expected, univariable Cox
models fitted with the single GSSs were greatly outper-
formed by their multivariable versions, yielding -respec-
tively- an average (st.dev) c-index of 0.6277 (0.007),
0.6271 (0.007), and 0.6330 (0.007). Additionally, a likeli-
hood-ratio-test conducted on the Cox regression, consid-
ering a null model with the sole GSS and an extended
model with all covariates, reported a consistently worse
fit of the null model as compared to the extended model
(Lnull = -7573.536, Lextended = -7361.47, c
2 = 424.13 on 41
degrees of freedom, p < 0.0001).
The c-index performance of RSF, grown with the lim-
ited number of 30 trees due to the high computational
burden, using the same covariate settings as in the multi-
variable Cox regression, were 0.7298 (0.009) for Rega,
0.7276 (0.009) for ANRS, and 0.7319 (0.008) for HIVdb.
By executing all pairwise Student’s t-tests (adjusted for
multiple comparisons with the Benjamini-Hochberg
method) comparing the c-index distributions, we find sta-
tistically significant differences between univariable vs.
multivariable Cox models, univariable Cox models vs.
RSF, and multivariable Cox models vs. RSF (all p <
0.0001). When comparing the performance of Rega,
ANRS and HIVdb within the same model settings, we
found evidence of a significantly better performance of
HIVdb as compared to ANRS in the univariable Cox (p <
0.0001), multivariable Cox and (p = 0.053), and RSF (p =
0.0005). HIVdb outperformed Rega only under the uni-
variable Cox modeling. Conversely, Rega and ANRS did
not show any appreciable difference in any of the within-
model c-index distributions. However, it has to be noted
that all the GSS had the same average c-index values up to
the third decimal.
When executing a sensitivity analysis on the subset of
treatment-naïve patients (n = 733), multivariable Cox
regression confirmed the relative hazards of the GSS of
the regimen (RH = 0.50, 95%CI 0.36-0.70, p < 0.0001, per
one point increase of HIVdb), and of HIV-1 RNA (RH =
1.51, 95%CI 1.15-1.97, p = 0.0026, per one Log10 copies/
ml higher). Other factors independently associated with
the endpoint were being non-Italian born (RH = 1.87,
95%CI 1.09-3.22, p = 0.023, as compared to Italian born),
subtype C (RH = 2.16, 95%CI 1.05-4.44, p = 0.036, as
compared to subtype B), and calendar year 2004 (RH =
2.08, 95%CI 1.31-3.31, p = 0.0019, as compared to 2007
and after). Differences among cART regimens were not
relevant.
In a second sensitivity analysis, only patients who
reached an HIV-1 RNA < = 50 copies/ml from the
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Numerical variables all patients ART-naive ART-experienced
median (IQR) median (IQR) median (IQR)
calendar year 2004 (2003-2006) 2006 (2004-2007) 2004 (2002-2005)
HIV-1 RNA log10 copies/ml 4.53 (3.83-5.12) 5.08 (4.63-5.5) 4.18 (3.63-4.8)
CD4+ count cells/mm3 273 (147-389) 191 (70-300) 296.8 (192-435)
Age years 40 (36-45) 39 (33-45) 40 (37-45)
GSS Rega 3 (2-3) 3 (3-3) 2 (1.5-3)
ANRS 3 (2-3) 3 (3-3) 2 (1.5-3)
HIVdb 3 (2-3) 3 (3-3) 2 (1.5-3)
Categorical variables n (%) n (%) n (%)
#patients 2158 733 (34.0%) 1425 (57.7%)
#cART regimens 2337 733 (31.4%) 1604 (68.6%)
cART type 2NRTI+1NNRTI 516 (23.9%) 235 (32.1%) 281 (19.7%)
2NRTI+1PI 243 (11.3%) 45 (6.1%) 198 (13.9%)
2NRTI+1PI/r 1306 (60.5%) 441 (60.2%) 865 (60.7%)
3NRTI 93 (4.3%) 12 (1.6%) 81 (5.7%)
gender male 1546 (71.6%) 563 (76.8%) 983 (69%)
previous AIDS-defining events (yes vs. no) 285 (13.2%) 92 (12.6%) 193 (13.5%)
Nationality Italian 1524 (70.6%) 529 (72.2%) 995 (69.8%)
non-Italian 168 (7.8%) 98 (13.4%) 70 (4.9%)
unknown 466 (21.6%) 106 (14.5%) 360 (25.3%)
mode of HIV-1 transmission heterosexual 657 (30.4%) 262 (35.7%) 395 (27.7%)
male homosexual 362 (16.8%) 154 (21%) 208 (14.6%)
IDU 468 (21.7%) 54 (7.4%) 414 (29.1%)
other/unknown 671 (31.1%) 263 (35.9%) 408 (28.6%)
HBV/HCV co-infection positive 605 (28%) 149 (20.3%) 456 (32%)
negative 483 (22.4%) 260 (35.5%) 223 (15.6%)
unknown 1070 (49.6%) 324 (44.2%) 746 (52.4%)
interval time from the first HIV-1 positive test to cART initiation < = 12 months 444 (20.6%) 354 (48.3%) 90 (6.3%)
> 12 and < = 60 months 188 (8.7%) 45 (6.1%) 143 (10%)
> 60 months 575 (26.6%) 61 (8.3%) 514 (36.1%)
unknown 951 (44.1%) 273 (37.2%) 678 (47.6%)
duration of prior ART exposures < = 6 months 1197 (55.5%) 733 (100%) 464 (32.6%)
> 6 and < = 12 months 117 (5.4%) N/A 117 (8.2%)
> 12 and < = 24 months 184 (8.5%) N/A 184 (12.9%)
> 24 months 660 (30.6%) N/A 660 (46.3%)
viral subtype B 1753 (81.2%) 503 (68.6%) 1250 (87.7%)
02_AG 56 (2.6%) 28 (3.8%) 28 (2%)
C 41 (1.9%) 31 (4.2%) 10 (0.7%)
F1 54 (2.5%) 39 (5.3%) 15 (1.1%)
other 60 (2.8%) 35 (4.8%) 25 (1.8%)
undetermined 194 (9%) 97 (13.2%) 97 (6.8%)
#previous ART switches none 733 (34%) 733 (100%) N/A
one/two 429 (19.9%) N/A 429 (30.1%)
three to six 605 (28%) N/A 605 (42.5%)
more than six 391 (18.1%) N/A 391 (27.4%)
previous exposure to suboptimal ART (yes vs. no) 922 (42.7%) N/A 922 (64.7%)
previous ART class exposure none 733 (34%) 733 (100%) N/A
only NRTI 94 (4.4%) N/A 94 (6.6%)
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NRTI and NNRTI 220 (10.2%) N/A 220 (15.4%)
NRTI, NNRTI and PI 252 (11.7%) N/A 252 (17.7%)
NRTI, NNRTI and PI/r 466 (21.6%) N/A 466 (32.7%)
NRTI and PI 229 (10.6%) N/A 229 (16.1%)
NRTI and PI/r 134 (6.2%) N/A 134 (9.4%)
other classes 30 (1.4%) N/A 30 (2.1%)
*cART: combination antiretroviral therapy; GSS: genotypic susceptibility score; ART: antiretroviral therapy; NRTI: nucleoside/tide reverse transcriptase inhibitors;
NNRTI: non-nucloeside reverse transcriptase inhibitors; PI: protease inhibitors; IDU: injecting drug users; HCV: hepatitis C virus; HBV: hepatitis B virus.
Table 2 Multivariable Cox proportional hazard model showing relative hazards (RH) for time-to-virologic-failure, fitted
on the whole study population (n = 2,337)
Factor RH 95% CI p-value
calendar year before 2004 vs. 2007 and after 2.06 (1.67-2.54) < 0.0001
2004 vs. after 2007 and after 1.62 (1.29-2.03) < 0.0001
2005-2006 vs. 2007 and after 1.28 (1.06-1.55) 0.0109
cART 2NRTI+1PI vs. 2NRTI+1NNRTI 1.03 (0.83-1.27) 0.8028
2NRTI+1PI/r vs. 2NRTI+1NNRTI 0.63 (0.54-0.75) < 0.0001
3NRTI vs. 2NRTI+1NNRTI 1.23 (0.92-1.64) 0.1599
age (per 10 years older) 0.89 (0.82-0.96) 0.0036
gender (male vs. female) 1.06 (0.91-1.23) 0.4668
mode of HIV-1 transmission male homosexual vs. heterosexual 1.08 (0.88-1.33) 0.4680
IDU vs. heterosexual 1.08 (0.87-1.32) 0.4898
other/unknown vs. heterosexual 1.08 (0.9-1.29) 0.4248
nationality non-Italian vs. Italian 1.23 (0.9-1.67) 0.1992
unknown vs. Italian 0.94 (0.78-1.14) 0.5475
HCV/HBV coinfection unknown vs. no 1.18 (0.97-1.45) 0.1049
yes vs. no 1.04 (0.82-1.32) 0.7277
HIV-1 RNA per log10 copies/ml higher 1.27 (1.17-1.39) < 0.0001
CD4+ count cells/mm3 < = 100 vs. > 500 1.57 (1.23-2) 0.0003
> 100 and < = 199 vs. > 500 1.16 (0.93-1.45) 0.1968
> 200 and < = 349 vs. > 500 1.22 (1-1.48) 0.0447
> 350 and < = 499 vs. > 500 0.98 (0.79-1.21) 0.8202
interval time from the first HIV-1 positive test to ART initiation < = 12 vs. > 60 months 0.87 (0.67-1.13) 0.2944
> 12 and < = 60 vs. > 60 months 1.01 (0.81-1.27) 0.9114
unknown vs. > 60 months 0.92 (0.77-1.11) 0.3938
duration of prior ART exposures < = 6 vs. > 24 months 0.84 (0.7-1.01) 0.0626
> 6 and < = 12 vs. > 24 months 0.92 (0.73-1.17) 0.5029
> 12 and < = 24 vs. > 24 months 0.83 (0.66-1.03) 0.0890
previous AIDS-defining events (yes vs. no) 0.86 (0.7-1.05) 0.1379
#previous ART switches 1.03 (1-1.05) 0.0522
previous ART class exposure NRTI vs. ART-naïve 1.48 (1.01-2.17) 0.0441
NRTI and NNRTI vs. ART-naïve 1.38 (0.99-1.93) 0.0546
NRTI and NNRTI and PI vs. ART-naïve 1.43 (1.03-1.99) 0.0315
NRTI and NNRTI and PI/r vs. ART-naïve 2.96 (2.16-4.06) < 0.0001
NRTI and PI vs. ART-naïve 2.18 (1.64-2.89) < 0.0001
NRTI and PI/r vs. ART-naïve 2.72 (1.98-3.75) < 0.0001
other classes vs. ART-naïve 2.31 (1.31-4.05) 0.0036
previous exposure to suboptimal ART (yes vs. no) 0.85 (0.71-1.03) 0.0946
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which 622 treatment-naïve). By fitting a multivariable
Cox regression, variables independently associated with
the endpoint were consistent with those obtained for
the subset of treatment-naïve patients (data not shown).
Discussion
In this study we investigated linear and non-linear survi-
val models for predicting the time to virologic failure in
HIV-1-infected patients undergoing a new cART regi-
men, with the aim to assess both prognostic factors of
virologic failure and performance of predictions, in light
of the development of a reliable expert system.
In contrast to 2NRTI+1PI/r, older age, higher HIV-1
RNA, and lower CD4+ counts, an increased hazard of
virologic failure was associated with low GSSs of cART,
a less recent calendar year, administration of 2NRTI
+1NNRTI, and the ART-naïve status. HIV-1 RNA and
GSS remained associated with the endpoint when con-
sidering only treatment-naïve patients in a sensitivity
analysis.
When looking at the goodness-of-fit of the models,
the inclusion of additional covariates besides the GSS in
a multivariable Cox regression yielded a significant
improvement in the likelihood. Furthermore, RSF
proved to be a promising approach, improving perfor-
mance over that obtained by using the Cox method.
This study has some limitations. First, there was a study
selection bias, since only cART regimens that were under-
taken for at least 90 days were considered. Early-switches
and simplifications were excluded from the analysis. In
addition, the main study endpoint was a pure virologic cri-
t e r i o na n dd i dn o ti n c l u d es t o p sd u et oo t h e rr e a s o n s .
Although we selected only clinics with the ability to per-
form ultra-sensitive assays, the viral load threshold at
> 400 copies/ml was arbitrary and might not capture all
the actual virologic failures. Other thresholds for defining
virologic failure, such as a viral load > 50 copies/ml or
> 1,000 copies/ml might overestimate or underestimate
true failure, respectively. We observed a lower hazard of
virologic failure for regimens containing ritonavir-boosted
PI as compared to those containing NNRTI, and this
might be a reflection of both the selection bias and the
endpoint definition.
In regards to the statistical methods, we did not investi-
gate the potential benefit in terms of likelihood fit given by
the inclusion of interaction terms in the Cox regression. It
is possible that a Cox model with higher-order interactions
is able to reach the performance obtained by using the
RSF. For the practical perspective of a time to event pre-
diction model, Cox regression presents some problems
with the baseline hazard function estimation, while the
RSF gives output in terms of mortality ensembles. We also
tested accelerated failure time models, which are able to
give reliable predictions in terms of actual time scales, and
their performance was comparable to the results of the
Cox regression (data not shown).
Table 2 Multivariable Cox proportional hazard model showing relative hazards (RH) for time-to-virologic-failure, fitted
on the whole study population (n = 2,337) (Continued)
viral subtype 02_AG vs. B 0.98 (0.61-1.57) 0.9402
C vs. B 1.41 (0.86-2.32) 0.1748
F1 vs. B 0.57 (0.3-1.06) 0.0750
other vs. B 1.26 (0.76-2.09) 0.3774
undetermined vs. B 1.12 (0.88-1.42) 0.3527
GSS* ANRS per 1 point increase 0.72 (0.66-0.78) < 0.0001
HIVdb per 1 point increase 0.68 (0.63-0.74) < 0.0001
Rega per 1 point increase 0.71 (0.66-0.77) < 0.0001
RH: relative hazard; CI: confidence interval; cART: combination antiretroviral therapy; NRTI: nucleoside/nucleotide reverse transcriptase inhibitors; NNRTI: non-
nucloeside reverse transcriptase inhibitors; PI: protease inhibitors; PI/r: ritonavir-boosted PI; IDU: injecting drug users; HCV: hepatitis C virus; HBV: hepatitis B virus;
ART: antiretroviral therapy; GSS: genotypic susceptibility score; *fitted separately one from each other.
Figure 1 Extra-sample performance evaluation of Cox
regression and Random Survival Forests models by means of
c-index distributions (100 bootstrap runs). Boxplots indicate
average and interquartile range, whilst whiskers indicate 95%
confidence intervals.
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This study demonstrates the feasibility of an expert sys-
tem that predicts the actual time course of a new cART
as the estimate of time to virologic failure, and the relia-
bility of the system’s predictions can be improved both
by including additional covariates besides the viral geno-
type and by using non-linear regression techniques. The
implementation of such a system would create a more
clinically-oriented treatment decision tool and more
effectively tailor patient cART regimens.
Additional material
Additional file 1: Supplementary material. Supplementary figures
describing performance and variable importance measures of Random
Survival Forests.
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